MaghrebDataLibMedV2, Main, Exploration, bibRecord, 000566

Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review.

Identifieur interne : 000566 ( Main/Exploration ); précédent : 000565; suivant : 000567

Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review.

Auteurs : Stephen Mac [Canada] ; Amanda Sumner [Canada] ; Samuel Duchesne-Belanger [Canada] ; Robert Stirling [Canada] ; Matthew Tunis [Canada] ; Beate Sander [Canada]

Source :

Pediatrics [ 1098-4275 ] ; 2019.

RBID : pubmed:31040196

Descripteurs français

KwdFr :
- Analyse coût-bénéfice (méthodes), Antiviraux (usage thérapeutique), Antiviraux (économie), Humains (MeSH), Infections à virus respiratoire syncytial (traitement médicamenteux), Infections à virus respiratoire syncytial (économie), Palivizumab (usage thérapeutique), Palivizumab (économie), Virus respiratoires syncytiaux (MeSH).
MESH :
- méthodes : Analyse coût-bénéfice.
- traitement médicamenteux : Infections à virus respiratoire syncytial.
- usage thérapeutique : Antiviraux, Palivizumab.
- économie : Antiviraux, Infections à virus respiratoire syncytial, Palivizumab.
- Humains, Virus respiratoires syncytiaux.

English descriptors

KwdEn :
- Antiviral Agents (economics), Antiviral Agents (therapeutic use), Cost-Benefit Analysis (methods), Humans (MeSH), Palivizumab (economics), Palivizumab (therapeutic use), Respiratory Syncytial Virus Infections (drug therapy), Respiratory Syncytial Virus Infections (economics), Respiratory Syncytial Viruses (MeSH).
MESH :
- chemical , economics : Antiviral Agents, Palivizumab.
- chemical , therapeutic use : Antiviral Agents, Palivizumab.
- drug therapy : Respiratory Syncytial Virus Infections.
- economics : Respiratory Syncytial Virus Infections.
- methods : Cost-Benefit Analysis.
- Humans, Respiratory Syncytial Viruses.

Abstract

CONTEXT

Palivizumab prophylaxis is used as passive immunization for respiratory syncytial virus (RSV). However, because of its high cost, the value of this intervention is unclear.

OBJECTIVE

To systematically review the cost-effectiveness of palivizumab prophylaxis compared with no prophylaxis in infants <24 months of age.

DATA SOURCES

Medline, Embase, and Cochrane Library up to August 2018.

STUDY SELECTION

Two reviewers independently screened results to include economic evaluations conducted between 2000 and 2018 from Organization for Economic Cooperation and Development countries.

DATA EXTRACTION

Two reviewers independently extracted outcomes. Quality appraisal was completed by using the Joanna Briggs Institute checklist. Costs were adjusted to 2017 US dollars.

RESULTS

We identified 28 economic evaluations (20 cost-utility analyses and 8 cost-effectiveness analyses); most were from the United States (

LIMITATIONS

Model design heterogeneity, model parameters, and study settings were barriers to definitive conclusions on palivizumab's economic value.

CONCLUSIONS

Palivizumab as RSV prophylaxis was considered cost-effective in prematurely born infants, infants with lung complications, and infants from remote communities.

DOI: 10.1542/peds.2018-4064
PubMed: 31040196

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000252
to stream PubMed, to step Curation: 000251
to stream PubMed, to step Checkpoint: 000271
to stream Main, to step Merge: 000566
to stream Main, to step Curation: 000566

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review.</title>
<author><name sortKey="Mac, Stephen" sort="Mac, Stephen" uniqKey="Mac S" first="Stephen" last="Mac">Stephen Mac</name>
<affiliation wicri:level="3"><nlm:affiliation>Toronto Health Economics and Technology Assessment Collaborative, University Health Network, Toronto, Canada; sm.mac@mail.utoronto.ca.</nlm:affiliation>
<country wicri:rule="url">Canada</country>
<wicri:regionArea>Toronto Health Economics and Technology Assessment Collaborative, University Health Network, Toronto</wicri:regionArea>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto</wicri:regionArea>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Sumner, Amanda" sort="Sumner, Amanda" uniqKey="Sumner A" first="Amanda" last="Sumner">Amanda Sumner</name>
<affiliation wicri:level="3"><nlm:affiliation>Public Health Agency of Canada, Ottawa, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Public Health Agency of Canada, Ottawa</wicri:regionArea>
<placeName><settlement type="city">Ottawa</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Duchesne Belanger, Samuel" sort="Duchesne Belanger, Samuel" uniqKey="Duchesne Belanger S" first="Samuel" last="Duchesne-Belanger">Samuel Duchesne-Belanger</name>
<affiliation wicri:level="3"><nlm:affiliation>Public Health Agency of Canada, Ottawa, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Public Health Agency of Canada, Ottawa</wicri:regionArea>
<placeName><settlement type="city">Ottawa</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stirling, Robert" sort="Stirling, Robert" uniqKey="Stirling R" first="Robert" last="Stirling">Robert Stirling</name>
<affiliation wicri:level="3"><nlm:affiliation>Public Health Agency of Canada, Ottawa, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Public Health Agency of Canada, Ottawa</wicri:regionArea>
<placeName><settlement type="city">Ottawa</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tunis, Matthew" sort="Tunis, Matthew" uniqKey="Tunis M" first="Matthew" last="Tunis">Matthew Tunis</name>
<affiliation wicri:level="3"><nlm:affiliation>Public Health Agency of Canada, Ottawa, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Public Health Agency of Canada, Ottawa</wicri:regionArea>
<placeName><settlement type="city">Ottawa</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sander, Beate" sort="Sander, Beate" uniqKey="Sander B" first="Beate" last="Sander">Beate Sander</name>
<affiliation wicri:level="3"><nlm:affiliation>Toronto Health Economics and Technology Assessment Collaborative, University Health Network, Toronto, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Health Economics and Technology Assessment Collaborative, University Health Network, Toronto</wicri:regionArea>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto</wicri:regionArea>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
<affiliation><nlm:affiliation>Institute of Clinical Evaluative Sciences, Toronto, Canada; and.</nlm:affiliation>
<wicri:noCountry code="subField">Canada; and</wicri:noCountry>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Public Health Ontario, Toronto, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Public Health Ontario, Toronto</wicri:regionArea>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:31040196</idno>
<idno type="pmid">31040196</idno>
<idno type="doi">10.1542/peds.2018-4064</idno>
<idno type="wicri:Area/PubMed/Corpus">000252</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000252</idno>
<idno type="wicri:Area/PubMed/Curation">000251</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000251</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000271</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000271</idno>
<idno type="wicri:Area/Main/Merge">000566</idno>
<idno type="wicri:Area/Main/Curation">000566</idno>
<idno type="wicri:Area/Main/Exploration">000566</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review.</title>
<author><name sortKey="Mac, Stephen" sort="Mac, Stephen" uniqKey="Mac S" first="Stephen" last="Mac">Stephen Mac</name>
<affiliation wicri:level="3"><nlm:affiliation>Toronto Health Economics and Technology Assessment Collaborative, University Health Network, Toronto, Canada; sm.mac@mail.utoronto.ca.</nlm:affiliation>
<country wicri:rule="url">Canada</country>
<wicri:regionArea>Toronto Health Economics and Technology Assessment Collaborative, University Health Network, Toronto</wicri:regionArea>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto</wicri:regionArea>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Sumner, Amanda" sort="Sumner, Amanda" uniqKey="Sumner A" first="Amanda" last="Sumner">Amanda Sumner</name>
<affiliation wicri:level="3"><nlm:affiliation>Public Health Agency of Canada, Ottawa, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Public Health Agency of Canada, Ottawa</wicri:regionArea>
<placeName><settlement type="city">Ottawa</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Duchesne Belanger, Samuel" sort="Duchesne Belanger, Samuel" uniqKey="Duchesne Belanger S" first="Samuel" last="Duchesne-Belanger">Samuel Duchesne-Belanger</name>
<affiliation wicri:level="3"><nlm:affiliation>Public Health Agency of Canada, Ottawa, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Public Health Agency of Canada, Ottawa</wicri:regionArea>
<placeName><settlement type="city">Ottawa</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stirling, Robert" sort="Stirling, Robert" uniqKey="Stirling R" first="Robert" last="Stirling">Robert Stirling</name>
<affiliation wicri:level="3"><nlm:affiliation>Public Health Agency of Canada, Ottawa, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Public Health Agency of Canada, Ottawa</wicri:regionArea>
<placeName><settlement type="city">Ottawa</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tunis, Matthew" sort="Tunis, Matthew" uniqKey="Tunis M" first="Matthew" last="Tunis">Matthew Tunis</name>
<affiliation wicri:level="3"><nlm:affiliation>Public Health Agency of Canada, Ottawa, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Public Health Agency of Canada, Ottawa</wicri:regionArea>
<placeName><settlement type="city">Ottawa</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sander, Beate" sort="Sander, Beate" uniqKey="Sander B" first="Beate" last="Sander">Beate Sander</name>
<affiliation wicri:level="3"><nlm:affiliation>Toronto Health Economics and Technology Assessment Collaborative, University Health Network, Toronto, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Health Economics and Technology Assessment Collaborative, University Health Network, Toronto</wicri:regionArea>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto</wicri:regionArea>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
<affiliation><nlm:affiliation>Institute of Clinical Evaluative Sciences, Toronto, Canada; and.</nlm:affiliation>
<wicri:noCountry code="subField">Canada; and</wicri:noCountry>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Public Health Ontario, Toronto, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Public Health Ontario, Toronto</wicri:regionArea>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Pediatrics</title>
<idno type="eISSN">1098-4275</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (economics)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Cost-Benefit Analysis (methods)</term>
<term>Humans (MeSH)</term>
<term>Palivizumab (economics)</term>
<term>Palivizumab (therapeutic use)</term>
<term>Respiratory Syncytial Virus Infections (drug therapy)</term>
<term>Respiratory Syncytial Virus Infections (economics)</term>
<term>Respiratory Syncytial Viruses (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Analyse coût-bénéfice (méthodes)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Antiviraux (économie)</term>
<term>Humains (MeSH)</term>
<term>Infections à virus respiratoire syncytial (traitement médicamenteux)</term>
<term>Infections à virus respiratoire syncytial (économie)</term>
<term>Palivizumab (usage thérapeutique)</term>
<term>Palivizumab (économie)</term>
<term>Virus respiratoires syncytiaux (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antiviral Agents</term>
<term>Palivizumab</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Palivizumab</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Respiratory Syncytial Virus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Respiratory Syncytial Virus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Cost-Benefit Analysis</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Analyse coût-bénéfice</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à virus respiratoire syncytial</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
<term>Palivizumab</term>
</keywords>
<keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Antiviraux</term>
<term>Infections à virus respiratoire syncytial</term>
<term>Palivizumab</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Respiratory Syncytial Viruses</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Virus respiratoires syncytiaux</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>CONTEXT</b>
</p>
<p>Palivizumab prophylaxis is used as passive immunization for respiratory syncytial virus (RSV). However, because of its high cost, the value of this intervention is unclear.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b>
</p>
<p>To systematically review the cost-effectiveness of palivizumab prophylaxis compared with no prophylaxis in infants <24 months of age.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>DATA SOURCES</b>
</p>
<p>Medline, Embase, and Cochrane Library up to August 2018.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>STUDY SELECTION</b>
</p>
<p>Two reviewers independently screened results to include economic evaluations conducted between 2000 and 2018 from Organization for Economic Cooperation and Development countries.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>DATA EXTRACTION</b>
</p>
<p>Two reviewers independently extracted outcomes. Quality appraisal was completed by using the Joanna Briggs Institute checklist. Costs were adjusted to 2017 US dollars.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>We identified 28 economic evaluations (20 cost-utility analyses and 8 cost-effectiveness analyses); most were from the United States (</p>
</div>
<div type="abstract" xml:lang="en"><p><b>LIMITATIONS</b>
</p>
<p>Model design heterogeneity, model parameters, and study settings were barriers to definitive conclusions on palivizumab's economic value.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>Palivizumab as RSV prophylaxis was considered cost-effective in prematurely born infants, infants with lung complications, and infants from remote communities.</p>
</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
<region><li>Ontario</li>
</region>
<settlement><li>Ottawa</li>
<li>Toronto</li>
</settlement>
<orgName><li>Université de Toronto</li>
</orgName>
</list>
<tree><country name="Canada"><region name="Ontario"><name sortKey="Mac, Stephen" sort="Mac, Stephen" uniqKey="Mac S" first="Stephen" last="Mac">Stephen Mac</name>
</region>
<name sortKey="Duchesne Belanger, Samuel" sort="Duchesne Belanger, Samuel" uniqKey="Duchesne Belanger S" first="Samuel" last="Duchesne-Belanger">Samuel Duchesne-Belanger</name>
<name sortKey="Mac, Stephen" sort="Mac, Stephen" uniqKey="Mac S" first="Stephen" last="Mac">Stephen Mac</name>
<name sortKey="Sander, Beate" sort="Sander, Beate" uniqKey="Sander B" first="Beate" last="Sander">Beate Sander</name>
<name sortKey="Sander, Beate" sort="Sander, Beate" uniqKey="Sander B" first="Beate" last="Sander">Beate Sander</name>
<name sortKey="Sander, Beate" sort="Sander, Beate" uniqKey="Sander B" first="Beate" last="Sander">Beate Sander</name>
<name sortKey="Stirling, Robert" sort="Stirling, Robert" uniqKey="Stirling R" first="Robert" last="Stirling">Robert Stirling</name>
<name sortKey="Sumner, Amanda" sort="Sumner, Amanda" uniqKey="Sumner A" first="Amanda" last="Sumner">Amanda Sumner</name>
<name sortKey="Tunis, Matthew" sort="Tunis, Matthew" uniqKey="Tunis M" first="Matthew" last="Tunis">Matthew Tunis</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/MaghrebDataLibMedV2/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000566 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000566 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    MaghrebDataLibMedV2
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:31040196
   |texte=   Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:31040196" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a MaghrebDataLibMedV2

This area was generated with Dilib version V0.6.38.
Data generation: Wed Jun 30 18:27:05 2021. Site generation: Wed Jun 30 18:34:21 2021

	Serveur sur les données et bibliothèques médicales au Maghreb (version finale)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur sur les données et bibliothèques médicales au Maghreb (version finale)

Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review.

Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki